The Johns Hopkins University was awarded a $5,797,615 Project Grant from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to conduct the "DRIVING PRESSURE-LIMITED VENTILATION IN HYPOXEMIC RESPIRATORY FAILURE (DRIVE-USA)" research project. This 2-year grant, awarded on June 1, 2024, will support basic, applied, and advanced biomedical research to investigate medical solutions for the battlefield and transform healthcare for military service members and...
The Johns Hopkins University was awarded a $974,999.00 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The three-year grant, spanning August 1, 2023 to July 31, 2026, will support research to engineer an effective combination therapy of car T cells and regulatory T cells to control rejection of vascularized composite allografts. This research aims to develop medical solutions for the battlefield and transform healthcare for...
The Johns Hopkins University has been awarded a $1,099,238 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) with a period of performance from September 1, 2024 to August 31, 2026. This grant will support investigator-initiated biomedical research projects across multiple medical disciplines to improve health outcomes for military service members, veterans, and the broader public. The award enables Johns Hopkins to conduct...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $823,267 project grant to The Johns Hopkins University to conduct research on "Mitochondrial Heteroplasmy as a Novel Risk Factor for Myelodysplastic Syndromes". The research project will run from August 1, 2025 to July 31, 2028 and aims to investigate innovative approaches to address critical health challenges relevant to military personnel and the broader public. As a leading...
The Department of Defense's Defense Health Agency awarded a $318,483 Project Grant to The Johns Hopkins University under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Specifically, the funding will be used for a 2-year project to quantitatively measure acute and chronic lesion activity in a real-world, multi-site clinical MRI...
The Johns Hopkins University received a $248,356 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "Cardiometabolic Comorbidity and Outcomes in Multiple Sclerosis: A Polygenic Risk Score Approach". The award period runs from September 1, 2023 to August 31, 2025. The project aims to investigate medical solutions for the battlefield through innovative and impactful biomedical research....
This $1,473,430 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports The Johns Hopkins University's research on pluripotent stem cell-derived corneal endothelial cells for the treatment of combat laser-induced corneal edema and vision restoration. Spanning from September 1, 2024 to August 31, 2027, this award will enable Johns Hopkins to conduct innovative biomedical research to develop new treatments for military...
The U.S. Department of Defense's Defense Health Agency awarded a $1,738,924 Project Grant to The Johns Hopkins University to conduct research on "Proteomics of Atrioventricular Septal Defect in Down Syndrome" from September 1, 2024 through August 31, 2028. This research, funded under the Military Medical Research and Development program (CFDA 12.420), aims to advance scientific understanding and treatment of this condition impacting military members, veterans, and their families. The...
This $1,473,750 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports The Johns Hopkins University's research study on "The Immunomodulatory Impact of Chemotherapy When Combined with PD-1 Blockade in Resectable Lung Cancer." The 3-year grant, running from September 1, 2024 to August 31, 2027, aims to investigate innovative immunological interventions for treating lung cancer in military service...
The U.S. Defense Health Agency awarded a $621,011 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Johns Hopkins University. The grant, with a performance period from July 1, 2025 to June 30, 2027, will fund research targeting sensory neurons via anti-CGRP therapies in osteosarcoma. As a leading federal contractor and grantee, The Johns Hopkins University has demonstrated extensive capabilities in advanced biomedical research across diverse medical...